This second webinar, in a four-part series on liquid biopsy and ILC, brings together a unique panel including surgical and medical oncologists and a patient advocate to discuss ctDNA testing in the early stage setting. The panel discussed current work to understand how liquid biopsies can guide surgical and treatment decisions, and monitor health after treatment.
Where Things Stand with ctDNA Testing for Early Stage ILC Before or After Surgery
Presenter(s):
Dr. Rinath Jeselsohn, LBCA Scientific Advisory Board Immediate Past Chair, Assistant Professor of Medicine at Harvard Medical School,and Medical Oncologist at Dana-Farber Cancer Institute
Dr. Megan Kruse, Director of Breast Medical Oncology, Co-Leader of the Breast Cancer Program, and Medical Director of the Taussig Cancer Center Clinical Trials Office at Cleveland Clinic, LBCA Scientific Advisory Board Member
Dr. Rita Mukhtar, Professor of Clinical Surgery at the University of California, San Francisco
Barbara Neilsen, Patient Advocate
If you missed to first session, click here.